To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the effect of cytochrome P450 3A4 enzyme
(CYP3A4) induction by rifampicin on the pharmacokinetics (PK) of eribulin mesylate following
intravenous (IV) administration in participants with advanced solid tumors. The secondary
objectives of this study were to assess the safety of eribulin mesylate when co-administered
with rifampicin and assess the safety and activity of eribulin mesylate as a single agent.